Product Information
LETROZOLE 2.5 MG TABLET is a generic product labeled by Accord Healthcare Inc., priced at $0.1450 per EA under NDC 16729003415. Its NADAC has been published 615 times since Dec 24, 2014.
FDA first approved this application on Jun 3, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Accord Healthcare Inc.NDC
16729003415
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LETROZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA090934FDA Approved
6/3/2011
TE Code
AB
On Market Since
6/2/2011
Pharmacological Classes
Price Statistics
The NADAC for LETROZOLE 2.5 MG TABLET has been published 615 times since Dec 24, 2014, and over the history we have for it it has declined 12.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1450 per EA |
|---|---|
| All-time high | $0.1951 (Feb 10, 2016) |
| All-time low | $0.1009 (Jun 21, 2023) |
| 52-week high | $0.1535 |
| 52-week low | $0.1292 |
| Median price | $0.1418 |
| Average price | $0.1422 |
| Largest weekly change | +32.3% (Nov 22, 2023) |
| Weeks tracked | 615 |
| Tracking since | Dec 24, 2014 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Accord Healthcare Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
letrozole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LETROZOLE 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LETROZOLE 2.5 MG TABLET, manufactured by Accord Healthcare Inc., is $0.1450 per EA (NDC 16729003415), effective Sep 30, 2026.
How has the price of LETROZOLE 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for LETROZOLE 2.5 MG TABLET has declined 12.4%. It has been tracked across 615 weekly CMS publications since Dec 24, 2014.
What are the highest and lowest recorded NADAC prices for LETROZOLE 2.5 MG TABLET?
Since Dec 24, 2014, the NADAC for LETROZOLE 2.5 MG TABLET has ranged from a low of $0.1009 (Jun 21, 2023) to a high of $0.1951 (Feb 10, 2016), with a median of $0.1418 per EA.
Are there cheaper alternatives to LETROZOLE 2.5 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LETROZOLE 2.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LETROZOLE 2.5 MG TABLET?
LETROZOLE 2.5 MG TABLET (NDC 16729003415) is labeled by Accord Healthcare Inc., and CMS classifies it as a generic product.